Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

已完结 100 由 Aixuexi 发布于 2026/1/4 13:41:47

DOI:10.1200/JCO-24-02834
作者：Mirat Shah,?Ting-Yu Chen,?Gwynn Ison,?Mallorie H Fiero,?Hui Zhang,?Xin Gao,?Marc Neilson,?Kirsten B Goldberg,?Abhilasha Nair,?Tiffany K Ricks,?William F Pierce,?Nicole Gormley,?Marc R Theoret,?Shenghu
文献类型：期刊论文
补充材料：只需要正文

American Society of Clinical Oncology (ASCO)

Abstract：From 2014 through 2019, the US Food and Drug Administration (FDA) granted approval to six indications for poly (ADP-ribose) polymerase (PARP) inhibitors in advanced epithelial ovarian cancer

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Iron-Catalyzed Site-Selective Bromination of Benzylic C(sp3)–H Bonds